Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yuka Shidahara"'
Publikováno v:
Journal of pain research. 15
Kazutaka Nozawa,1 Yusuke Karasawa,1 Yuka Shidahara,2 Takahiro Ushida3 1Medical Affairs, Viatris Pharmaceuticals Japan Inc., Minato-ku, Tokyo, Japan; 2Bioscience Business Division, KAC Co., Ltd, Ritto, Shiga, Japan; 3Multidisciplinary Pain Center, Aic
Autor:
Yoshifumi Shirakami, Kenta Kurimoto, Masanori Takeuchi, Atsushi Toyoshima, Atsushi Shinohara, Kazuko Kaneda-Nakashima, Yuwei Liu, Yuka Shidahara, Takashi Murai, Kenji Okuma, Masayuki Nishide, Tadashi Watabe, Kazuhiro Ooe
Publikováno v:
Annals of Nuclear Medicine. 35:702-718
Objective Astatine (211At) is a promising alpha emitter as an alternative to iodine (131I). We are preparing the first-in-human (FIH) clinical trial of targeted alpha therapy for differentiated thyroid cancer in consultation with Pharmaceuticals and
Autor:
Tadashi, Watabe, Kazuko, Kaneda-Nakashima, Kazuhiro, Ooe, Yuwei, Liu, Kenta, Kurimoto, Takashi, Murai, Yuka, Shidahara, Kenji, Okuma, Masanori, Takeuchi, Masayuki, Nishide, Atsushi, Toyoshima, Atsushi, Shinohara, Yoshifumi, Shirakami
Publikováno v:
Annals of Nuclear Medicine
Objective Astatine (211At) is a promising alpha emitter as an alternative to iodine (131I). We are preparing the first-in-human (FIH) clinical trial of targeted alpha therapy for differentiated thyroid cancer in consultation with Pharmaceuticals and
Autor:
Ikuo Hayashi, Shinya Ogawa, Yasuhiro Magata, Hiroyuki Takamatsu, Kurumi Yamoto, Takahiro Natsume, Yuka Shidahara, Aldric Hama, Shinichi Okamoto, Yūji Awaga
Publikováno v:
Neuropharmacology. 149
The antineoplastic agent oxaliplatin is a first-line treatment for colorectal cancer. However, neuropathic pain, characterized by hypersensitivity to cold, emerges soon after treatment. In severe instances, dose reduction or curtailing treatment may
Autor:
Aldric Hama, Miyuki Takashima, Mari Nakamura, Yuji Awaga, Akihisa Matsuda, Hiroyuki Takamatsu, Yuka Shidahara, Shinya Ogawa, Nemoto Shingo
Publikováno v:
Pharmacology Research & Perspectives
Oxaliplatin is a first‐line treatment for colorectal cancer. However, shortly following treatment, cold‐evoked hypersensitivity appears in the extremities and over time, the pain is such that oxaliplatin dosing may need to be markedly reduced or